Hematological Neoplasms

Yescarta, also known as Axicabtagene Ciloleucel (Axi-Cel) or 奕凯达 (阿基伦塞) in Chinese, is a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen.

Yescarta (Axicabtagene ciloleucel, Axi-cel) has revolutionized the treatment landscape for lymphoma since its initial approval by the US FDA on October 18, 2017. As the world’s first chimeric antigen receptor T-cell (CAR-T) therapy for adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have received two or more lines of systemic therapy, Yescarta has ushered in a new era in lymphoma treatment.

In the realm of oncology, the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) has witnessed significant advancements over the past decade.

The ZUMA-7 trial, a randomized, open-label, multicenter Phase III study, represents a pivotal moment in the Yescarta narrative.

One such therapy is Yescarta (axicabtagene ciloleucel), a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy that specifically targets the CD19 antigen.

Yescarta, also known as axicabtagene ciloleucel, is a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy that has been hailed as a significant breakthrough in the treatment of certain types of lymphoma.

Yescarta, a groundbreaking chimeric antigen receptor (CAR) T-cell therapy, has revolutionized the treatment landscape for certain types of lymphoma.

In the field of oncology, the advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of certain types of cancer, particularly lymphomas.